Literature DB >> 28849410

Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.

Yana Anfinogenova1,2, Elena V Grakova3, Maria Shvedova4, Kristina V Kopieva3, Alexander T Teplyakov3, Sergey V Popov3.   

Abstract

Diabetes mellitus is a chronic disease requiring lifelong control with hypoglycemic agents that must demonstrate excellent efficacy and safety profiles. In patients taking glucose-lowering drugs, hypoglycemia is a common cause of death associated with arrhythmias, increased thrombus formation, and specific effects of catecholamines due to sympathoadrenal activation. Focus is now shifting from merely glycemic control to multifactorial approach. In the context of individual drugs and classes, this article reviews interdisciplinary strategies evaluating metabolic effects of drugs for treatment of chronic heart failure (CHF) which can mask characteristic hypoglycemia symptoms. Hypoglycemia unawareness and cardiac autonomic neuropathy are discussed. Data suggesting that hypoglycemia modulates immune response are reviewed. The potential role of gut microbiota in improving health of patients with diabetes and CHF is emphasized. Reports stating that nondiabetic CHF patients can have life-threatening hypoglycemia associated with imbalance of thyroid hormones are discussed. Regular glycemic control based on HbA1c measurements and adequate pharmacotherapy remain the priorities in diabetes management. New antihyperglycemic drugs with safer profiles should be preferred in vulnerable CHF patients. Multidrug interactions must be considered. Emerging therapies with reduced hypoglycemia risk, telemedicine, sensor technologies, and genetic testing predicting hypoglycemia risk may help solving the challenges of hypoglycemia in CHF patients with diabetes. Interdisciplinary work may involve cardiologists, diabetologists/endocrinologists, immunologists, gastroenterologists, microbiologists, nutritionists, imaging specialists, geneticists, telemedicine experts, and other relevant specialists. This review emphasizes that systematic knowledge on pathophysiology of hypoglycemia in diabetic patients with CHF is largely lacking and the gaps in our understanding require further discoveries.

Entities:  

Keywords:  Chronic heart failure; Diabetes; Hypoglycemia; Hypoglycemia unawareness; Interdisciplinary

Mesh:

Substances:

Year:  2018        PMID: 28849410     DOI: 10.1007/s10741-017-9647-y

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  160 in total

Review 1.  Hypoglycaemia unawareness.

Authors:  G B Bolli
Journal:  Diabetes Metab       Date:  1997-09       Impact factor: 6.041

Review 2.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

3.  Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users.

Authors:  Anthony P Nunes; Kristy Iglay; Larry Radican; Samuel S Engel; Jing Yang; Michael C Doherty; David D Dore
Journal:  Diabetes Obes Metab       Date:  2017-07-21       Impact factor: 6.577

4.  Severe hypoglycemia associated with levofloxacin in Type 2 diabetic patients receiving polytherapy: two case reports.

Authors:  Lucia Micheli; Marcello Sbrilli; Cristina Nencini
Journal:  Int J Clin Pharmacol Ther       Date:  2012-04       Impact factor: 1.366

Review 5.  Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control.

Authors:  A J Scheen; N Esser; N Paquot
Journal:  Diabetes Metab       Date:  2015-03-18       Impact factor: 6.041

6.  Threshold-based insulin-pump interruption for reduction of hypoglycemia.

Authors:  Richard M Bergenstal; David C Klonoff; Satish K Garg; Bruce W Bode; Melissa Meredith; Robert H Slover; Andrew J Ahmann; John B Welsh; Scott W Lee; Francine R Kaufman
Journal:  N Engl J Med       Date:  2013-06-22       Impact factor: 91.245

7.  Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation.

Authors:  James T Pearson; Mathew J Jenkins; Amanda J Edgley; Takashi Sonobe; Mandar Joshi; Mark T Waddingham; Yutaka Fujii; Daryl O Schwenke; Hirotsugu Tsuchimochi; Misa Yoshimoto; Keiji Umetani; Darren J Kelly; Mikiyasu Shirai
Journal:  Cardiovasc Diabetol       Date:  2013-08-01       Impact factor: 9.951

8.  Effects of Acute and Antecedent Hypoglycemia on Endothelial Function and Markers of Atherothrombotic Balance in Healthy Humans.

Authors:  Nino G Joy; Donna B Tate; Lisa M Younk; Stephen N Davis
Journal:  Diabetes       Date:  2015-02-18       Impact factor: 9.461

9.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

10.  The hypoglycemic side of hypothyroidism.

Authors:  Sanjay Kalra; Ambika Gopalakrishnan Unnikrishnan; Rakesh Sahay
Journal:  Indian J Endocrinol Metab       Date:  2014-01
View more
  1 in total

1.  Decreased blood glucose at admission has a prognostic impact in patients with severely decompensated acute heart failure complicated with diabetes mellitus.

Authors:  Akihiro Shirakabe; Noritake Hata; Nobuaki Kobayashi; Hirotake Okazaki; Masato Matsushita; Yusaku Shibata; Suguru Nishigoori; Saori Uchiyama; Kazutaka Kiuchi; Fumitaka Okajima; Toshiaki Otsuka; Kuniya Asai; Wataru Shimizu
Journal:  Heart Vessels       Date:  2018-03-22       Impact factor: 2.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.